紫杉醇联合奈达铂治疗晚期非小细胞肺癌

目的 评价紫杉醇联合奈达铂治疗晚期非小细胞肺癌的疗效和毒副反应.方法 33例经病理确诊的晚期非小细胞肺癌患者,初治或复治,ⅢB期(伴胸腔积液)或Ⅳ期,重要脏器功能正常,PS评分0～2分的患者入组.紫杉醇175 mg/m2,第1天,奈达铂80 mg/m2,第1天,每21 d为一疗程.结果 本组33例患者均已完成至少2个疗程化疗.初治组和复治组的有效率分别为41.1％、31.3％,中位生存期分别为425 d和343 d.发生白细胞减少和血小板减少的疗程数分别占总疗程数的65.5％和19％,无治疗相关性死亡.结论 紫杉醇联合奈达铂治疗晚期非小细胞肺癌,疗效确切,对顺铂耐药患者仍然有效,耐受性好.

A clinical study of nedaplatin combined with paclitaxel in treatment for advanced non-small cell lung cancer

Objective To observe the safety and efficacy of nedaplatin plus paclitaxel in treatment of advanced non-small cell lung cancer(NSCLC).Methods Patients with NSCLC,no matter weather previously treated,either stage ⅢB with pleural effusion or stage Ⅳ,were enrolled if they had a performance status of 0~2,and had adequate organ function.The respectively doses of nedaplatin day 1 and paclitaxel days 1 were 80 mg/m2 and 175 mg/m2,repeated every 21 days.Results 33 patients got the above regimen for at least 2 cycles,of them,17(The initial treatment group)were untreated before and 16(Retreatment group)had previously received chemotherapy.The overall response rate were 41.1% vs 31.3%,and the median survival time were 425 days vs 343 days in The initial treatment group and Retreatment group respectively.The overall rates of neutropenia and thrombocytopenia were 65.5% and 19% in all 33 courses,calculated by course.There were no treatment-related deaths.Conclusion Nedaplatin combined with paclitaxel is an effective and safe treatment regimen for advanced NSCLC patients,even in those resistant to cisplatin.